BP CFO says retail fuel demand has shown some weakness.

INIBO, a Korean botulinum-toxin product in which Huaxi Bio has a strategic stake, received approval from the National Medical Products Administration; Huaxi is the exclusive mainland China partner. The arrangement combines strategic investment and market cooperation to broaden Huaxi’s medical-aesthetics product coverage, diversify its business mix and support long-term development. This extends a prior exclusive-agency collaboration with Korea’s INIBIO for a facial-rejuvenation injection.

Mark Dowding at BlueBay Asset Management said in a report that as corporates are expected to ramp up debt issuance, the investment appeal of AI-related corporate bonds is weakening. He said the anticipated wave of AI-related bond and equity issuance may struggle to find sufficient demand, adding: "Investors will have to sell assets to make room for the large volume of new supply about to hit the market."